ALZpath Finds Surge in Medicare p-tau Testing Claims

Phosphorylated tau testing claims under Medicare Part B rose sharply from late 2025 through April 2026, according to a real-world analysis.

Updated on Nov. 18, 2026 in Alzheimer’s

Bold flat-color editorial illustration of unlabeled glass test vials stepping upward in height across a navy and cream field with an amber accent, suggesting rising diagnostic test adoption.
Medicare Part B claims for the blood-based Alzheimer's test p-tau rose from 5,379 in December 2025 to 12,623 in April 2026, according to an ALZpath analysis. AI Illustration. Upload story photo >

Live Poll

Would you feel confident your insurance would cover an Alzheimer's blood test?

ALZpath released findings from a real-world analysis of phosphorylated tau (p-tau) testing claims under Medicare Part B. Monthly claims rose from 5,379 in December 2025 to 12,623 in April 2026, and 77.5% of the 95,900 unique claims received a nonzero Medicare payment.

Why it matters

The analysis tracks how quickly a blood-based diagnostic for Alzheimer's disease is being adopted and reimbursed in the United States. Rising payments per claim and total spending highlight how coverage decisions and test availability may shape access for patients evaluated for the disease across the country.

The analysis covered 95,900 unique claims, of which 77.5% received a nonzero Medicare payment, with monthly claims rising from 5,379 in December 2025 to 12,623 in April 2026. The majority of claims were associated with laboratory-developed tests, and how reimbursement will shift as FDA-cleared tests become more available remains unknown.

The players

ALZpath

ALZpath is a company focused on developing diagnostic tests for Alzheimer's disease, including phosphorylated tau assays used in blood-based testing.

Clinical Trials on Alzheimer's Disease (CTAD)

CTAD is a major international scientific conference where researchers present clinical trial and diagnostic findings related to Alzheimer's disease.

The details

The study examined claims submitted under CPT code 84393, which covers phosphorylated tau testing in plasma and cerebrospinal fluid, using data covering January 2025 through April 2026. A subset of 42,380 claims with an associated venipuncture code showed reimbursement rates similar to the full dataset.

Timeline

  1. January 2025 through April 2026: Period covered by the claims analysis.

  2. December 2025: Monthly p-tau claims totaled 5,379.

  3. April 2026: Monthly p-tau claims reached 12,623.

  4. November 19, 2026: Findings to be presented at the Clinical Trials on Alzheimer's Disease conference in Boston.

Health Landscape

The rapid growth in Medicare p-tau claims reflects the broader shift toward blood-based biomarkers for Alzheimer's disease, which are gradually replacing more invasive cerebrospinal fluid and imaging-based approaches in routine evaluation. Medicare reimbursement levels are emerging as a key factor in how quickly these tests spread into everyday clinical care.

For patients being evaluated for memory problems, rising availability and Medicare coverage of p-tau blood tests may make earlier diagnostic testing more accessible. Out-of-pocket costs and insurance coverage can still vary depending on the test type and setting.

The takeaway

Growing Medicare payments for blood-based p-tau testing signal that Alzheimer's diagnostics are moving from specialty settings into wider clinical use. Patients concerned about memory changes can discuss available testing options with their physicians.

What happens next

Findings from the analysis will be presented at the Clinical Trials on Alzheimer's Disease conference in Boston on November 19, 2026.

Further reading

Explore more on Alzheimer’s research and diagnostic developments in the United States.

Live Poll

Would you feel confident your insurance would cover an Alzheimer's blood test?